ElectroKidney OAC Kidney-on-a-chip for disease modeling and drug development

• Grant number: 22/14769-3
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: February 01, 2023
• End date: January 31, 2024
• Field of knowledge: Health Sciences - Medicine
• Agreement: FINEP - Centelha SP Program
• Principal Investigator: Silviene Novikoff
• Grantee: Silviene Novikoff
• Company: Silviene Novikoff
• CNAE: Comércio varejista de outros produtos novos não especificados anteriormente ; Pesquisa e desenvolvimento experimental em ciências físicas e naturais ; Atividades profissionais, científicas e técnicas não especificadas anteriormente
• Pesquisadores principais: Thiago Rafael Rodrigues Ribeiro
• Associated researchers: Niels Olsen Saraiva Câmara ; Tiago Albertini Balbino
• Associated research grant(s): 22/16128-5 - ElectroKidney OAC Kidney-on-a-chip for disease modeling and drug development, AP.PIPE
• Associated scholarship(s): 23/01831-5 - Electro kidney OAC kidney-on-a-chip for disease modeling and drug development, BP.PIPE

Abstract

Our startup seeks to be in tune with trends in the organ-on-chip (OoC) market, responding to pressing demands, not yet met by the national market, from researchers, industry and Market Drivers, with an attractive value proposition. We use cutting-edge, emerging technology with great global impact with a disruptive business model (DaaS), providing the startup with recurring revenue with a high average dollarized ticket, in a market still in its infancy (blue sea) nationwide.Our proposal consists of a three-dimensional microphysiological device in vitro (organ-on-a-chip), used as an investigational technological platform to carry out co-cultures or spheroids of a variety of cells obtained by tissue bioengineering, allowing cell-cell interactions in a controlled microenvironment, which simulates one or more aspects of the dynamics, functionality and (patho)physiological response of the organ in vivo and biomarker profile in-vitro, under real-time monitoring.Primarily, we use kidney cells to recreate human kidney tissue for nephrotoxicity testing, drug development and disease modeling, in order to develop alternative methodologies to the use of animals in experimentation and regenerative medicine. (AU)